Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of PRX-00023 in Major Depressive Disorder
NCT00448292Phase 2Completed
- Sponsor
- Epix Pharmaceuticals
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naluzotan in major depressive disorder (MDD), sponsored by Epix Pharmaceuticals. Started Mar 2007; status: completed.
02
Drugs
naluzotan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00448292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448292.